Subgroup analysis indicated that KRT17 overexpression was significantly associated with better OS in BC patients with T1 andT2 stage (p = 0.047), T3 andT4 stage (p = 0.042), N2 and N3 stage (p = 0.014), M0 stage (p = 0.0008) and clinical pathologic stage III and IV (p = 0.005) disease (Figure 2B,C,E,F,I). Here, KRT17 is linked to breast cancer.